Cannabis Law Report

JULY 1, 2021

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. While psychedelic therapies make their way through the drug development pipeline, seven U.S.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

JUNE 20, 2021

The CIC consists of 97 members dedicated to ensuring a greater understanding of the role of medicinal cannabis, nutraceutical CBD, and hemp across the community and the advancement of medicinal cannabis as an alternate line of therapy. Patient access.

Supply Chain 105

Supply Chain Clinical Trials Research and Development Medicine 105

Cannabis Law Report

JUNE 24, 2022

Scutari’s proposed “Psilocybin Behavioral Health Access and Services Act” represents a bold development in the psychedelics reform movement that’s rapidly spread in state legislatures and through citizen-led initiatives throughout the country in recent years. Full story at.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

JANUARY 12, 2022

Today, Maya (Maya PBC) and the National Psychedelics Association (NPA) announced their partnership in support of the implementation of Oregon’s Measure 109, the first state-approved policy to allow the regulated use of psilocybin products in a facilitated setting.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). About MAPS Public Benefit Corporation (MAPS PBC). Executive Summary.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

OCTOBER 10, 2021

Cantourage is an innovative company ensuring that patients are able to access the newest medicinal products based on cannabis. We at Cantourage share the belief that cannabis is a valuable medicine which until now has not gained enough attention as a therapy option. pharmacology, toxicology, chemistry). Advanced degree preferred.

Clinical Trials 52

Clinical Trials Therapy Medicine Policy 52

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.

Legislation 161

Legislation Decriminalization Access Therapy 161

Cannabis Law Report

MARCH 29, 2022

We are thrilled to have Michael’s expertise guiding the development of MDMA-assisted therapy for PTSD! Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

Cannabis Law Report

MAY 29, 2022

FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 11 × 11. In 2017, the FDA designated MDMA a breakthrough therapy for PTSD.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

NOVEMBER 23, 2021

In a draft paper, Patents on Psychedelics: The Next Legal Battlefront of Drug Development , Senior Fellow at Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics Mason Marks and Harvard Law School Professor I.

Law 52

Law Research and Development Therapy Clinical Trials 52

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

JULY 25, 2022

Conversation Tackles MAPS Research Methadology & Issues Of Abuse In Therapy. Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. Psychedelics Today Podcast Interviews Rick Doblin.

Medicine 52

Medicine Therapy Research and Development Business 52

Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. For two decades, U.S.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JUNE 3, 2022

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Legalization 59

Legalization Clinical Trials Compliance Compliance 59

Cannabis Law Report

MARCH 1, 2022

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

OCTOBER 2, 2021

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

AUGUST 7, 2022

In recent years, as more clinical trial results show that psychedelics can be used in conjunction with therapy to treat illnesses like depression and post-traumatic stress disorder, legislators pushed to make certain substances available in certain settings. Psychedelic Alpha Policy Map. Where Laws Are Changing.

Law 74

Law Research and Development Therapy Treatment 74

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Amanda Feilding, Countess of Wemyss and March is an English drug policy reformer, lobbyist and research coordinator. Andrew Yang.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

DECEMBER 30, 2019

Now, nearly 1 in 4 Americans reside in a jurisdiction where the adult use of cannabis is legal, and 33 states regulate medical marijuana access. After this historically successful year, we expect to see public and political support continue to increase in 2020 as more and more states implement sensible cannabis regulatory policies.

Legislation 59

Legislation Patients Access Banking 59